Jiaxing AnDiCon Biotech Co.,Ltd
Quick facts
Phase 3 pipeline
- ADC189 tablet · Oncology
ADC189 is an antibody-drug conjugate that targets a specific tumor-associated antigen to deliver cytotoxic payload directly to cancer cells. - ADC189 tablets · Oncology
ADC189 is an antibody-drug conjugate that targets a specific tumor-associated antigen to deliver cytotoxic payload directly to cancer cells. - Baloxavir Marboxil tablets · Virology/Infectious Disease
Baloxavir marboxil inhibits the influenza virus endonuclease, blocking viral cap-dependent transcription and preventing viral replication. - Placebo of ADC189 granules
This is a placebo control formulation used in clinical trials and contains no active pharmaceutical ingredient. - Placebo of ADC189 tablets
This is a placebo control formulation used in clinical trials and contains no active pharmaceutical ingredient. - Placebo of Baloxavir Marboxil tablets · Virology/Influenza
This is a placebo control formulation with no active pharmacological mechanism.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Jiaxing AnDiCon Biotech Co.,Ltd portfolio CI brief
- Jiaxing AnDiCon Biotech Co.,Ltd pipeline updates RSS
Frequently asked questions about Jiaxing AnDiCon Biotech Co.,Ltd
What is Jiaxing AnDiCon Biotech Co.,Ltd's pipeline?
Jiaxing AnDiCon Biotech Co.,Ltd has 6 drugs in Phase 3, 0 in Phase 2, 2 in Phase 1. Late-stage candidates include ADC189 tablet, ADC189 tablets, Baloxavir Marboxil tablets, Placebo of ADC189 granules.
Related
- Sector hub: All tracked pharma companies